Adicet bio to participate in 2024 canaccord genuity horizons in oncology virtual conference

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that chen schor, president and chief executive officer will participate in a panel at the canaccord genuity horizons in oncology virtual conference being held april 15, 2024. details of the event are as follows: panel: “off-the-shelf cart – let's talk lupus an.
ACET Ratings Summary
ACET Quant Ranking